Compare iShares International Treasury Bond ETF (IGOV) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Nuwellis Inc — how do they compare? iShares International Treasury Bond ETF trades at $39.75 (market cap $1.30B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares International Treasury Bond ETF is far larger — about 590.9× Nuwellis Inc's market cap, and iShares International Treasury Bond ETF is more actively traded (693,740 versus 121,544). Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Nuwellis Inc for 26 Days on average.
| IGOV | NUWE | |
|---|---|---|
Market Cap | $1.30B | $2.20M |
Volume | 693,740 | 121,544 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $146.65 |
52-Week Low | $39.65 | $0.68 |
Typical Hold Time | 92 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.70, down 0.48% with a bearish technical outlook as moving averages signal selling pressure. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental assessment. Recent news highlights rising global bond yields, which may impact interest-rate sensitive sectors. The stock shows neutral oscillator signals with RSI levels near oversold territory at 30-37.
Investment outlook remains cautious due to incomplete financial data and bearish technical indicators. Rising Treasury yields pose macroeconomic headwinds, while the absence of valuation metrics complicates risk-reward analysis. Investors require updated SEC filings and earnings reports to properly evaluate the company's financial health and growth prospects.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
